Double-Blind Comparison of Intravenous Cyclophosphamide and Intrathecal Methotrexate Plus Dexamethasone in Neuropsychiatric Lupus Erythematosus Patients

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR1900002487

Enrollment

Unknown

Registered

2019-07-22

Start date

2019-07-23

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropsychiatric Lupus Erythematosus

Interventions

1:Intravenous Cyclophosphamide

2:Intrathecal Methotrexate Plus Dexamethasone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients were diagnosed as NPSLE, younger than 65 years old, with normal blood routine and liver and kidney function.

Exclusion criteria

Exclusion criteria: Patients with leukopenia; cardiopulmonary insufficiency; patients with central nervous system infection; unable to accept lumbar puncture therapy; there are also 1) patients who are participating in other clinical trials; 2) Researchers believe that other reasons are not suitable for clinical trials.

Design outcomes

Primary

Measure	Time frame
Cerebrospinal fluid;	—

Secondary

Measure	Time frame
Symptom relief time;Incidence of toxic and side effects;	—

Countries

China

Contacts

Public ContactZhang yongwen

Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine

651543010@qq.com+86 13914749684

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026